Amgen

Results: 561



#Item
151Australian & New Zealand Bone & Mineral Society Issue 13 inside this issue

Australian & New Zealand Bone & Mineral Society Issue 13 inside this issue

Add to Reading List

Source URL: www.anzbms.org.au

Language: English - Date: 2015-02-22 22:52:46
152Genetic engineering / Bioengineering / Emerging technologies / Genetically modified organism / Therapeutic Goods Administration / Agriculture / GMO / Biology / Molecular biology / Biotechnology

Questions & Answers on licence application DIR 132 – Commercial release of a tumour-selective genetically modified virus for cancer therapy What is this application for? Amgen Australia Pty Ltd (Amgen) is seeking appro

Add to Reading List

Source URL: www.ogtr.gov.au

Language: English - Date: 2015-03-06 01:48:49
153Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the Oncologic Drugs Advisory Committee Meeting January 7, 2015 Location: FDA White Oak Campus, Building 31, the Great Room, White Oa

Food and Drug Administration Center for Drug Evaluation and Research Summary Minutes of the Oncologic Drugs Advisory Committee Meeting January 7, 2015 Location: FDA White Oak Campus, Building 31, the Great Room, White Oa

Add to Reading List

Source URL: www.fda.gov

Language: English
154NOTIFICATION OF APPLICATION Receipt of licence application (DIR 132) from Amgen Australia Pty Ltd for the commercial release of a tumour-selective genetically modified organism for cancer therapy Application The Office o

NOTIFICATION OF APPLICATION Receipt of licence application (DIR 132) from Amgen Australia Pty Ltd for the commercial release of a tumour-selective genetically modified organism for cancer therapy Application The Office o

Add to Reading List

Source URL: www.ogtr.gov.au

Language: English - Date: 2015-03-06 01:37:31
155ANZBMS – 25 September 2014 e-Newsletter  ANZBMS e-News 25 September[removed]ASBMR Young Investigator Award

ANZBMS – 25 September 2014 e-Newsletter ANZBMS e-News 25 September[removed]ASBMR Young Investigator Award

Add to Reading List

Source URL: www.anzbms.org.au

Language: English - Date: 2015-02-22 23:10:40
156PATIENT INFORMATION ON  DENOSUMAB Brand name: Prolia This information sheet has been produced by the Australian Rheumatology Association to help

PATIENT INFORMATION ON DENOSUMAB Brand name: Prolia This information sheet has been produced by the Australian Rheumatology Association to help

Add to Reading List

Source URL: www.rheumatology.org.au

Language: English - Date: 2014-01-16 18:36:35
157Bekanntmachung zu den Endgültigen Bedingungen vom[removed]für UBS Turbo Call/Put Optionsscheine mit den nachfolgenden ISINs bezogen auf den Kurs der Aktie der Alibaba Group Holding Limited CH0271423300

Bekanntmachung zu den Endgültigen Bedingungen vom[removed]für UBS Turbo Call/Put Optionsscheine mit den nachfolgenden ISINs bezogen auf den Kurs der Aktie der Alibaba Group Holding Limited CH0271423300

Add to Reading List

Source URL: keyinvest-at.ubs.com

Language: English - Date: 2015-03-08 16:16:20
158Bekanntmachung zu den Endgültigen Bedingungen vom[removed]für UBS Turbo Call/Put Optionsscheine mit den nachfolgenden ISINs bezogen auf den Kurs der Aktie der Alibaba Group Holding Limited CH0271423300

Bekanntmachung zu den Endgültigen Bedingungen vom[removed]für UBS Turbo Call/Put Optionsscheine mit den nachfolgenden ISINs bezogen auf den Kurs der Aktie der Alibaba Group Holding Limited CH0271423300

Add to Reading List

Source URL: keyinvest-de.ubs.com

Language: English - Date: 2015-03-08 14:58:46
159Bekanntmachung zu den Endgültigen Bedingungen vom[removed]für UBS Turbo Call/Put Optionsscheine mit den nachfolgenden ISINs bezogen auf den Kurs der Aktie der Alibaba Group Holding Limited CH0271423300

Bekanntmachung zu den Endgültigen Bedingungen vom[removed]für UBS Turbo Call/Put Optionsscheine mit den nachfolgenden ISINs bezogen auf den Kurs der Aktie der Alibaba Group Holding Limited CH0271423300

Add to Reading List

Source URL: keyinvest-lu.ubs.com

Language: English - Date: 2015-03-08 14:53:52
160™  Denosumab (Prolia ) STRONG EVIDENCE IN THE CASE AGAINST OSTEOPOROSIS  Kristin L. Pareja, Pharm.D.

™ Denosumab (Prolia ) STRONG EVIDENCE IN THE CASE AGAINST OSTEOPOROSIS Kristin L. Pareja, Pharm.D.

Add to Reading List

Source URL: www.utexas.edu

Language: English - Date: 2011-01-20 10:06:53